Sentiment Trading

Pulmatrix Inc. is merging with Cullgen and plans to divest several assets, including its migraine treatment candidate, as part of a broader corporate update.

Pulmatrix, Inc. is a clinical-stage biotech company with promising therapies for chronic respiratory diseases, but its financial stability and market performance raise concerns about its future prospects.

Pulmatrix, Inc. is a biotech company focused on developing innovative therapies for chronic respiratory diseases, including cystic fibrosis and idiopathic pulmonary fibrosis.